Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SGN-30 · 3 trials · 7 indications
| Name | Type | Description |
|---|---|---|
| SGN-30 | DRUG | - |
| SGN-30 (anti-CD30 mAb) | DRUG | - |
| SGN-30 (monoclonal antibody) | DRUG | - |
Inclusion Criteria * Patients must have a definite diagnosis. * Patients must be histologically confirmed CD30 positive within 3 months of enrollment * Patients with pcALCL must have target lesions present for at least 1 month without spontaneous regression * pcALCL patients must have failed treatm...
SGN-30 is an investigational antibody being studied for the treatment of CD30-positive hematologic malignancies, including anaplastic large-cell lymphoma, large cell lymphoma, and Hodgkin disease. It has been evaluated in patients with refractory or recurrent forms of these conditions.
SGN-30 targets CD30, a cell surface protein expressed on certain malignant cells. It is designed to bind to CD30-positive cells in hematologic malignancies such as Hodgkin disease and anaplastic large-cell lymphoma.
SGN-30 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE.
SGN-30 has completed Phase 2 clinical trials. It is an investigational drug and has not been approved by the FDA. Its development status is based on completed trials in patients with CD30-positive hematologic malignancies.
SGN-30 has been studied in three completed clinical trials: NCT00051597 (Phase 1, refractory or recurrent CD30+ hematologic malignancies), NCT00079755 (Phase 2, refractory or recurrent anaplastic large cell lymphoma), and NCT00099255 (Phase 2, primary cutaneous anaplastic large cell lymphoma).
No, SGN-30 is a naked anti-CD30 antibody, not an antibody-drug conjugate. It is distinct from brentuximab vedotin, which is a CD30-directed antibody-drug conjugate. SGN-30 is an investigational agent developed by Pfizer.